22nd Century Group Inc XXII

NAS: XXII | ISIN: US90137F1030   3/05/2024
1,670 USD (-0,60%)
(-0,60%)   3/05/2024

29 december 2021 · La FDA autorise la commercialisation des cigarettes VLN® de 22nd Century Group en tant que produit du tabac à risque modifié · Persbericht

19 maart 2021 · Becerra Confirmation Boosts 22nd Century’s Position to Disrupt Tobacco Industry · Persbericht

12 maart 2021 · 22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants · Persbericht

11 maart 2021 · 22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020 · Persbericht

5 maart 2021 · 22nd Century Group to Participate in Investor Conferences in March 2021 · Persbericht

4 maart 2021 · 22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants · Persbericht

25 februari 2021 · 22nd Century Group to Host Webcast to Discuss Fourth Quarter and Full-Year 2020 Results · Persbericht

24 februari 2021 · 22nd Century Group Provides Business Update Letter from CEO · Persbericht

10 februari 2021 · 22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits · Persbericht

28 januari 2021 · 22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District · Persbericht

26 januari 2021 · The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes · Persbericht

19 januari 2021 · Federal Court Dismisses Securities Class Action Lawsuit Against 22nd Century Group · Persbericht

13 januari 2021 · 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes · Persbericht

11 januari 2021 · 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes · Persbericht

Mijn selecties